The programmed death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway is the primary site of cancer immunotherapy, and its activity and expression may predict prognosis, treatment sensitivity, immune response, invasion, metastasis to lymph nodes and distant sites, and appearance of adverse events and cancer symptoms of PC [173–177]. The gene discussed is CD274; the disease is cancer.